Clinical trial BOT112-02
Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal junction cancer
Cancers | |
---|---|
Organ | Multiple |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 2 |
Academic trial | Non |
Sponsor | Highlight Therapeutics S.L. |
EudraCT Identifier | 2019-004624-38 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04508140 |
Inclusion criteria | unresectable liver metastases |
Last update |